Skip to main content
. 2019 Apr 18;74(2):347–362.e6. doi: 10.1016/j.molcel.2019.02.010

Figure 7.

Figure 7

Chimeric FBD-Parkin Can Compensate for Loss of TBK1 or Receptor Proteins during Mitophagy

(A) Model for the bypass experiment performed using FIP200-binding peptide-Parkin (FBD-Parkin) in WT, TBK1 KO, or 5KO (OPTN, NDP52, Tax1bp1, NBR1, p62) cells.

(B) Mitophagy analysis by FACS. WT HeLa cells, TBK1 KO, or 5KO cells expressing mito-mKeima and FBD-Parkin.

(C and D) (C) FBD-Parkin (E230R/E241R) or (D) FBD-Parkin (K211N) were treated with OA and QVD for 6 h.

All FACS quantifications: n = 3 biological replicates. Data are represented as mean ± SD. p value: ∗ = < 0.05; ∗∗ < 0.01; ∗∗∗ < 0.001; ∗∗∗∗ < 0.00001; ns., not significant.

See also Figure S3.